Compare OMEX & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | BMRA |
|---|---|---|
| Founded | 1986 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.8M | 8.2M |
| IPO Year | N/A | N/A |
| Metric | OMEX | BMRA |
|---|---|---|
| Price | $2.34 | $2.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 873.6K | 20.8K |
| Earning Date | 11-12-2025 | 01-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $467,122.00 | ★ $4,884,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $2.08 |
| 52 Week High | $4.43 | $10.16 |
| Indicator | OMEX | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 57.12 |
| Support Level | $2.08 | $2.43 |
| Resistance Level | $2.23 | $2.67 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 98.60 | 84.46 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. The company provides specialized mineral exploration, project development, and marine services to clients. It is engaged in the discovery, validation, and development of subsea mineral deposits in a socially and environmentally responsible manner. The company works with governments to identify mineral resources in Exclusive Economic Zones, focusing on phosphorite (fertilizer) and polymetallic nodules (battery metals) projects. Its projects include the ExO Phosphate project, CIC, Ocean Minerals, and the LIHIR Gold project.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.